Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation

Area of Science:

• Molecular Biology
• Oncology
• Veterinary Medicine

Background:

• Gliomas are frequent brain tumors in dogs, but their causes are not fully understood.
• Mutations in isocitrate dehydrogenase 2 (IDH2) are implicated in human gliomas, particularly at the Arg172 codon.
• Limited information exists on canine IDH2 structure, function, and mutations.

Purpose of the Study:

• To investigate the functional and potential carcinogenic effects of canine IDH2 mutations.
• To characterize the role of canine IDH2 R174K mutation in cellular processes relevant to gliomagenesis.

Main Methods:

• Cloned full-length canine IDH2 (cIDH2) cDNA and created a specific mutation (R174K).
• Overexpressed wild-type (WT) and mutant cIDH2 proteins in HeLa cells.
• Assessed IDH2 enzyme activity by measuring NADH and NADPH production.
• Quantified hypoxia-inducible factor-1 alpha (HIF-1α) expression.

Main Results:

• Confirmed successful overexpression of cIDH2 WT and R174K proteins.
• Observed significantly lower NADPH production in cells expressing cIDH2 R174K compared to cIDH2 WT.
• Detected elevated levels of HIF-1α in cIDH2 R174K transfectants.

Conclusions:

• The canine IDH2 R174K mutation leads to reduced enzyme activity and increased HIF-1α expression.
• These findings suggest that IDH2 mutations at R174 may contribute to canine gliomagenesis.
• This research provides insights into the molecular mechanisms of canine gliomas.